{"id":"W2169700609","doi":"10.1200/jco.2012.46.4149","title":"Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer","year":2013,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":215,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of British Columbia","funders":"Takeda Oncology; Sanofi; Teva Pharmaceutical Industries; Genentech; AstraZeneca; Bristol-Myers Squibb; Amgen","keywords":"Medicine; Docetaxel; Placebo; Prostate cancer; Internal medicine; Clinical endpoint; Peripheral edema; Adverse effect; Nausea; Hazard ratio; Oncology; Urology; Cancer; Randomized controlled trial; Surgery; Confidence interval; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001547976,0.001381451,0.003339458,0.000416145,0.0004290849,0.0009194591,0.0008857002,0.001180823,0.003656941],"category_scores_gemma":[0.001477355,0.0006216517,0.001070593,0.0004988303,0.001134433,0.0005880856,0.0002642923,0.002235056,0.0006155382],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007792372,"about_ca_system_score_gemma":0.001692059,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001145788,"about_ca_topic_score_gemma":0.003588135,"domain_scores_codex":[0.999387,0.0003338659,0.00003376195,0.00009747011,0.00006226187,0.00008562324],"domain_scores_gemma":[0.9991714,0.0001630055,0.0002183265,0.00004723262,0.00005654456,0.0003434564],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9590715,0.01522785,0.00116123,0.0006430367,0.0009992428,0.00005233945,0.00006169442,0.0004212423,0.005420322,0.000100831,0.0008482469,0.01599249],"study_design_scores_gemma":[0.908048,0.08923272,0.001369823,0.00001441662,0.0002428957,0.00002332713,0.00001409143,0.0002645511,0.0003189215,0.00004666502,0.0004171337,0.000007503342],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9822505,0.005130836,0.0009965295,0.0005848999,0.0006643384,0.007564542,0.0008151665,0.0001312302,0.001861937],"genre_scores_gemma":[0.984597,0.003071001,0.001661887,0.000933731,0.0004301841,0.006286075,0.0006879696,0.00001947994,0.002312671],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003656941,"threshold_uncertainty_score":0.01223373,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06085388927927497,"score_gpt":0.4502794007597806,"score_spread":0.3894255114805056,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}